KRÜGER Martin
No ORCID on file
· 49 papers in corpus
· active 2002-2005
Frequent coauthors
- MENRAD Andreas 49
- THIERAUCH Karl-Heinz 49
- HABEREY Martin 49
- HUTH Andreas 49
- ERNST Alexander 35
- ZORN Ludwig 14
- HESS-STUMP Holger 14
- INCE Stuart 14
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to selective anthranilamide pyridine amides as inhibitors of VEGFR-2 and VEGFR-3 and to their production and use as medicaments for treating diseases that are caused by persistent angiogenesis. The inventive compounds …
2004
The invention relates to selective anthranilamide pyridine amides as inhibitors of VEGFR-2 and VEGFR-3 and to their production and use as medicaments for treating diseases that are caused by persistent angiogenesis. The inventive compounds …
2004
The invention relates to selective anthranilamide pyridine amides as inhibitors of VEGFR-2 and VEGFR-3 and to their production and use as medicaments for treating diseases that are caused by persistent angiogenesis. The inventive compounds …
2004
The invention relates to selective anthranilamide pyridine amides as inhibitors of VEGFR-2 and VEGFR-3 and to their production and use as medicaments for treating diseases that are caused by persistent angiogenesis. The inventive compounds …